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Aberrant activation of the Janus kinase (JAK)/signal transducer
and activator of transcription (STAT) pathway has been
reported to promote proliferation and survival of Hodgkin and
Reed–Sternberg cells of Hodgkin lymphoma (HL). We investi-
gated the activity of the JAK inhibitor AZD1480 in HL-derived
cell lines and determined its mechanisms of action. AZD1480 at
low doses (0.1–1lM) potently inhibited STATs phosphorylation,
but did not predictably result in antiproliferative effects, as it
activated a negative-feedback loop causing phosphorylation of
JAK2 and extracellular signal-regulated kinases 1 and 2 (ERK1/2),
and increased IP-10, RANTES and interleukin (IL)-8 concen-
trations in the supernatants. Inhibition of the ERK activity by
mitogen-activated extracellular signal regulated kinase (MEK)
inhibitors (UO126 and PD98059) enhanced the cytotoxic activity
of AZD1480. Interestingly, submicromolar concentrations of
AZD1480 demonstrated signiﬁcant immunoregulatory effects
by downregulating T-helper 2 cytokines and chemokines,
including IL-13 and thymus- and activation-regulated chemo-
kine, and the surface expression of the immunosuppressive
programmed death ligands 1 and 2. Higher concentrations of
AZD1480 (5lM) induced G2/M arrest and cell death by inhibiting
Aurora kinases. Our study demonstrates that AZD1480 reg-
ulates proliferation and immunity in HL cell lines and provides
mechanistic rationale for evaluating AZD1480 alone or in
combination with MEK inhibitors in HL.
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Introduction
The Janus kinase (JAK)/signal transducer and activator of
transcription (STAT) pathway has been linked to the oncogenic
process of a variety of cancers, including Hodgkin lymphoma
(HL), making it an appealing target for a pathway-directed
cancer therapy.
1–4 JAK/STAT activation is primarily driven by an
aberrant deregulation of a network of cytokine and chemokines
in the HL microenvironment (autocrine and paracrine loops
involving a variety of cytokines such as, interleukin (IL)-6 and
IL-13).
1,2,4 In rare cases, genomic gains of JAK2 and inactivating
mutations of suppressors of cytokine signaling (SOCS) proteins
have also been linked to the JAK/STAT activation in HL.
5,6 After
the cytokine receptor is engaged, members of the JAK family
(JAK1, JAK2, JAK3 and tyrosine (Tyr) kinase 2 (TYK2)) are
phosphorylated, and in turn, they phosphorylate downstream
STAT proteins at Tyr residues. This leads to STAT proteins
dimerization and translocation to the nucleus, where they
trigger the transcription of target genes involved in cell
proliferation and survival.
7
Recent studies highlight the importance of the JAK-STAT
pathway for mechanisms of immune escape in HL.
8,9 STAT6
activation in Hodgkin Reed–Sternberg cells (HRS) cells leads to
the secretion of the immunosuppressive thymus- and activation-
regulated chemokine (TARC/CCL17), with consequent attraction
and homing of T-helper 2 (Th2) cells in areas surrounding the
HRS cells and consequent impairment of immune response.
8
Another mechanism of tumor immune evasion is the interaction
between the programmed cell death 1receptor in tumor inﬁltrating
T cells with its programmed death ligand (PD-L) 1 and 2 (PD-L1
(CD274, B7-H1) and PD-L2 (CD273, B7-DC)) expressed on
the cell surface of a variety of tumor types, including HL,
primary mediastinal B-cell lymphoma and anaplastic large T-cell
lymphoma.
9–12 The engagement of programmed cell death 1
receptor by PD-L1 and PD-L2, leads to inhibition of T-cell func-
tion, promotes apoptosis of cytotoxic T cells and the induction
of immunosuppressive T-regulatory cells, leading to a decrease
in tumor killing.
10 Recently, the JAK/STAT pathway has been
shown to be involved in the regulation of PD-L1 and PD-L2
expression in HL and anaplastic large cell lymphoma cells.
9,11,13
AZD1480 is a novel pyrazol pyrimidine ATP-competitive
inhibitor of JAK1 and 2 kinases, with IC50’s of 1.3 and o0.4nM,
respectively, in enzyme assays. AZD1480 has been shown to
inhibit the STAT3 phosphorylation in vitro and in an in vivo
xenograft model of human solid tumors and multiple myelo-
ma.
14,15 At higher concentrations, AZD1480 has also been
shown to inhibit other JAK family members and Aurora A kinase
in puriﬁed enzyme assays.
14 Because of the reported addiction
of HL cells on JAK/STAT signaling pathway, we investigated the
antiproliferative activity of AZD1480 in HL-derived cell lines
and examined its mechanism of action with the aim to identify
potential predictive molecular markers for response and
resistance that can be validated in future in the clinical setting.
We report that AZD1480 at low doses (0.1–1mM) inhibited
constitutive STATs phosphorylation in HL cell lines, demonstrat-
ing immunoregulatory effects as it downregulated the surface
expression of the STAT3-target immunosuppressive cell-surface
protein PD-L1 and PD-L2, in addition to downregulation of
IL-13, IL-6 and TARC. However, inhibition of STATs phospho-
rylation resulted in signiﬁcant antiproliferative activity in only
one cell line. In the resistant cell lines, AZD1480 paradoxically
activated extracellular signal-regulated kinases 1 and 2 (ERK1/2)
and increased the secretion of the chemokines interferon g-induced
protein 10kDa (IP-10), RANTES and IL-8.
When higher doses (5mM) were used, its antiproliferative
activity was independent of STATs inhibition and due to
inhibition of Aurora kinases.
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mechanism of action, as it regulates immunity and proliferation
in HL cell lines. Furthermore, these results provide a framework
for investigating AZD1480 alone or in combination with ERK
inhibitors in HL.
Materials and methods
Cell lines
The human HRS-derived cell lines HD-LM2, L-428, KM-H2 and
L-540 were obtained from the German Collection of Micro-
organisms and Cell Cultures, Department of Human and Animal
Cell Cultures (Braunschweig, Germany) in 2009, and were
tested and authenticated before using them by the MD Anderson
Characterized Cell Lines Core Facility. The phenotypes and
genotypes of these cell lines have been previously described.
16
The L-428 and KM-H2 cell lines were cultured in RPMI 1640
medium supplemented with 10% heat-inactivated fetal bovine
serum (GIBCO BRL, Gaithersburg, MD, USA), 1% L-glutamine
and penicillin–streptomycin in a humid environment of 5% CO2
at 371C. The HD-LM2 and L-540 cell lines were cultured in
RPMI 1640 medium supplemented with 20% heat-inactivated
fetal bovine serum. Peripheral blood samples were obtained
from three healthy donors and peripheral blood mononuclear
cells (PBMCs) were isolated from these samples. The protocol
was approved by the Institutional Review Board of The
University of Texas MD Anderson Cancer Center; informed
consent was obtained from all donors.
Reagents and antibodies
The JAK2 inhibitor AZD1480 was obtained from AstraZeneca,
Inc. (Waltham, MA, USA). Nocodazole was purchased from
Sigma-Aldrich (St Louis, MO, USA), MG132 was purchased
from EMD Chemicals (San Diego, CA, USA), and the mitogen-
activated extracellular signal regulated kinase (MEK) inhibitors
UO126 and PD98059 were purchased from Cell Signaling
Technology (Beverly, MA, USA). For western blotting, anti-
bodies to the following were purchased from Cell Signaling
Technology: p-JAK1 (Y1022/1023), JAK1, p-JAK2 (Y1007/1008),
JAK2, JAK3, p-TYK2 (Y1054/1055), TYK2, STAT proteins (p-STAT1;
Y701), STAT1, p-STAT3 (Y705), STAT3, p-STAT5 (Y694), STAT5,
p-STAT6 (Y641), STAT6, p-ERK (Thr 202, Y204), ERK, p-Aurora
A (Thr 288), Aurora A, Aurora B, histone H3, caspase 9, cleaved
caspase 3, poly (adenosine diphosphate ribose) polymerase,
SOCS-3, p-p38 (Thr 180, Y182), p38, p-SHP-2 (Y542) and
SHP-2. Antibody to p-JAK2 (Y1007/1008)* was also purchased
from Abcam (Cambridge, MA, USA), antibody to p-JAK3 (Y980)
from Santa Cruz Biotechnology (Santa Cruz, CA, USA),
antibody to p-histone H3 (Ser 10) from Millipore (Temecula,
CA, USA) and antibody to b-actin from Sigma. For ﬂow
cytometry staining, antibodies to PD-L1 (PE-conjugated
B7-H1) were purchased from eBioscience (San Diego, CA,
USA) and to PD-L2 (PE-conjugated B7-DC) were from BD
Pharmingen (San Jose, CA, USA).
In-vitro proliferation assay
Cells were cultured in 24-well plates at 0.5 106cells/ml. Cell
viability was assessed with the nonradioactive cell proliferation
MTS [3-(4,5 dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl-2-
(4-sulfophenyl)-2H-tetrazolium] assay by using the CellTiter 96
AQueous One Solution Reagent (Promega, Madison, WI, USA)
as previously described.
8 Each measurement was made in
triplicate and the mean value was determined. Each results is
the mean of three independent experiments.
Western blotting
Preparation of cellular protein lysates, protein quantitation
and western immunoblotting were performed as previously
described.
17,18
Flow cytometry
Apoptosis was determined by using the Annexin V–FITC
apoptosis detection kit (BD Pharmingen, San Diego, CA, USA)
according to the manufacturer’s instructions. Cell cycle fractions
were determined by propidium iodide nuclear staining, as
previously described.
8 For PD-L1 and PD-L2 expression, after
incubation with AZD1480 1mM for 72h, cells were harvested,
washed twice in cold phosphate-buffered saline, 1% bovine
serum albumin, and stained with anti-B7-H1, B7-DC or mouse
IgG1 isotype control antibodies PE-conjugated for 20min. The
stained cells were washed twice in cold phosphate-buffered
saline, ﬁxed in 1% paraformaldehyde-phosphate-buffered saline
and then applied to the ﬂow cytometer. A total of 20000 events
were analyzed. Data were collected on a FACSCalibur ﬂow cyto-
meter (BD Biosciences, San Jose, CA, USA), using FlowJo software
(Tree Star, Ashland, OR, USA) as described previously.
8 Each
result is the mean of three independent experiments. Bar graphs
show the mean of three independent experiments±s.e.m.
Measurement of cytokines and chemokines
HL cell lines were incubated with AZD1480 (1mM) or dimethyl
sulfoxide (0.1%) for 72h. Supernatants were then collected and
examined for production of IL-13, IL-6, IP-10, RANTES and IL-8
by enzyme-linked immunosorbent assay, by using the human
cytokine 30-plex panel (Invitrogen, Carlsbad, CA, USA) and
for production of TARC by using the Human TARC ELISA kit
(RD Systems, Minneapolis, MN, USA), according to the manu-
facturers’ instructions. Each experiment was performed in
triplicate, and each result is the mean of three independent
experiments±s.e.m.
Statistical analyses
The effectiveness of the drugs used in this study, alone and
in combination, was analyzed by using CalcuSyn software
(Biosoft, Ferguson, MO, USA). The combination index (CI) was
calculated according to the Chou–Talalay method.
17,18 CI¼1
indicates an additive effect of two drugs, CI o1 indicates a
synergistic effect, and CI 41 indicates antagonism between the
two drugs. Procedures to determine the effects of certain
conditions on cell proliferation, cell cycle, apoptosis and
cytokine production were performed in three independent
experiments. The two-tailed Student’s t-test was used to estimate
the statistical signiﬁcance of the differences between results
from the three experiments. Signiﬁcance was set at Po0.05.
Results
Expression of activated JAK2 in cultured HL cells
To explore the potential therapeutic value of the JAK2 inhibitor
AZD1480 in HL, we initially examined the expression pattern
of its protein target, the active, phosphorylated form of JAK2
Y1007/1008, in cultured HL cells. We hypothesized that
cells with high levels of p-JAK2 would be more sensitive to
the antiproliferative effect of AZD1480 than cells with lower
levels of p-JAK2. We found p-JAK2 to be expressed in two
of the four HL cell lines (Figure 1a). None of the HL cell
lines expressed p-JAK1 Y1022/1023, two cell lines expressed
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Blood Cancer Journalp-TYK2 Y1054/1055, and only one cell line (L-540) expressed
p-JAK3 Y980 (Figure 1a). Thus, the activation pattern of the JAK
family members is rather heterogeneous in the HL cell lines.
Next, we investigated the expression pattern of the active
phosphorylated form of downstream (p-STATs). We found
p-STAT3, p-STAT5 and p-STAT6 to be expressed in the three
Figure 1 Baseline JAK/STAT pathway activation status and effects of AZD1480 in HL cell lines. (a) Baseline activation of the JAK/STAT pathway in
the HL cell lines HD-LM2, L-428, KM-H2 and L-540. PBMCs from three healthy donors were used for comparison. (b) Western blot assay of the
four HL cell lines treated with increasing doses of AZD1480 (0.1–5mm) for 72h. (c) MTS assay of the four HL cell lines treated with AZD1480.
Cells were incubated with increasing concentrations of AZD1480 (0.1–10mm) for 24, 48 and 72h. The value for each cell line is the mean of three
independent experiments performed in triplicate. Error bars represent s.e.m. (d)I C 50 values after HL cell lines were incubated with increasing doses
of AZD1480 for 72h.
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member of the JAK family: HD-LM2, L-428 and L-540
(Figure 1a). Consistent with a previous report, the KM-H2 cell
line did not express p-JAKs or p-STAT3, pSTAT5 or pSTAT6
proteins;
19 neither did the three samples of PBMCs isolated from
healthy donors. We found p-STAT1 to be expressed in all HL
cell lines and in only one PBMC sample from a healthy donor.
AZD1480 inhibits STAT3, STAT5 and STAT6
phosphorylation in HL cells
The differential expression of JAK/STAT family members in HL
cell lines gave us an opportunity to determine the biological
effect of AZD1480 in cells that have thee different patterns
of expression: HD-LM2 and L-428 (which expressed p-JAK2
and p-TYK2), L-540 (which expressed p-JAK3), and KM-H2
(which lacked p-JAKs expression). Increasing concentrations
of AZD1480 (0.1–5mM) inhibited STAT1, STAT3, STAT5 and
STAT6 phosphorylation in all three cell lines that showed
evidence of full JAK/STAT activation: HD-LM2, L-428 and L-540
(Figure 1b). These results suggest that in addition to JAK2,
AZD1480 may also inhibit JAK3 activity in HL cell lines. Potent
inhibition of STAT3 phosphorylation was observed as soon as
after 30min of incubation with AZD1480 and was maintained
up to 72h (Supplementary Figure S1A and B).
Antiproliferative effects of AZD1480 in HL cell lines
Previous studies have demonstrated that HL cell lines are
addicted to the JAK/STAT pathway, and selective inhibition of
STAT proteins by RNA interference has been shown to result in
antiproliferative effects in HL cell lines.
2 Because AZD1480
inhibited p-STAT3, p-STAT5 and p-STAT6, we investigated the
antiproliferative effect of AZD1480 in HL cells by using the MTS
assay. AZD1480 induced antiproliferative effects in a time- and
dose-dependent manner (Figure 1c). After 72h of incubation,
the half maximal inhibitory concentration (IC50) values for
AZD1480 ranged from 1 to 8mM; L-540 cells were the most
sensitive to AZD1480 (Figure 1c and d). Thus, although
submicromolar concentrations of AZD1480 inhibited STAT
phosphorylation, these low concentrations were not sufﬁcient
to induce a signiﬁcant antiproliferative activity, especially in the
HD-LM2 and L-428 cells. In contrast, at a higher concentration
(5mM), AZD1480 had a stronger effect in all cell lines, including
KM-H2, which lacked active JAK/STAT proteins. These data
suggest that at this higher concentration (5mM), AZD1480
induced antiproliferative effects in HL cell lines in a JAK/
STAT-independent manner.
To further investigate the mechanisms of the antiproliferative
activity of AZD1480, we determined the inhibitor’s effect on
apoptosis. Consistent with the MTS data in Figure 1c, we found
that AZD1480 induced apoptotic cell death in a dose-
dependent manner (Figure 2a and b). At the lower concentration
of AZD1480 (1mM), L-540 cells were the most sensitive (43.3%
cell death after 72h of incubation) and L-428 cells were
modestly sensitive (27.6% cell death). At the higher concentra-
tion (5mM), AZD1480 induced apoptosis in all four cell lines,
but L-540 cells remained the most sensitive. Consistent with
induction of apoptosis, AZD1480 activated caspases 9 and 3,
and induced poly (adenosine diphosphate ribose) polymerase
Figure 2 AZD1480 induces apoptosis in HL cell lines. (a) Representative experiment demonstrating the effect of two different doses of AZD1480
(1 or 5mm for 72h) on apoptosis as determined by annexin V-binding assay. The percentage of dead cells is shown in the upper right quadrant.
(b) Summary of the results of dual annexin V and propidium iodide (PI) staining. Each value is the mean of three independent experiments
performed in triplicate. *Po0.05; **Po0.005; NS, not signiﬁcant. Error bars represent s.e.m. (c) Immunoblotting showing activation of the intrinsic
apoptotic pathway in HL cell lines incubated with AZD1480 (1–5mm) for 72h. Consistent with the data in (a) and (b), cleavage of poly (adenosine
diphosphate ribose) polymerase (PARP) and activation of caspases 9 and 3 were observed in all the cell lines exposed to 5mm AZD1480. In L-540
and L-428, caspase cleavage was observed also with 1mm AZD1480.
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incubation with AZD1480 in all cell lines, when high doses
(5mM) were used (Supplementary Figure S1C).
AZD1480 induces paradoxical hyperphosphorylation of
JAK2 and TYK2 at the activation loop in HL cells
Although AZD1480 inhibited phosphorylation of STATs, its
effect on the phosphorylation of the JAK family members in HL
cells is unknown. Only the Tyr-phosphorylated forms of JAKs are
known to exhibit kinase activity, and phosphorylation at two
tandem Tyr residues in the activation loop appears to be
required for enzymatic activity.
20 As levels of baseline p-JAK2
expression and p-STATs inhibition did not predict sensitivity to
AZD1480 in HD-LM2 and L-428 cells, we investigated the
effect of AZD1480 on the phosphorylation status of the JAK
family members at the activation loop. To determine the effect
of AZD1480 on p-JAKs, we focused our experiments on the
three cell lines that expressed active JAK/STAT proteins:
HD-LM2, L-428 and L-540 (Figure 3a). In L-540, which was
Figure 3 AZD1480 induces paradoxical hyperphosphorylation of JAK2, TYK2 and MAP Kinases (ERK, p38) in HL cells. (a) Representative western
blot assay of the three HL cell lines treated with increasing concentrations of AZD 1480 (0.1–5mm for 72h). Whole-cell lysates examined for p-JAK2
(two antibodies against Y1007/1008 at the activation loop obtained from different clones (see Materials and Methods)), JAK2, p-TYK2 Y1054/1055,
TYK2, p-JAK3 Y980 and JAK3. (b) Representative western blot assay showing increased levels of ERK, p38 and SHP-2 phosphorylation in HD-LM2
and L-428, after treatment for 72h with increasing doses of AZD1480 (0.1–5mm). In contrast, L-540 showed a dose-dependent inhibition of ERK and
p38 activation without increased SHP-2 phosphorylation. SOCS-3 levels decreased in all the cell lines. (c) After incubation with 1mm AZD1480 for
72h, cell culture supernatants were analyzed for IL-8, IP-10 and RANTES levels by enzyme-linked immunosorbent assay. In the bar graphs, each
value is the mean of three independent experiments performed in triplicate. *Po0.05; **Po0.005; NS, not signiﬁcant. (d) Effect of MEK inhibitors
used with or without AZD1480 in HL cells. Combination index analysis performed using CalcuSyn software, showing that AZD1480 (1mm) acted
synergistically (CI o1) with UO126 or PD98059 (10–100mm) in HD-LM2 and L-428 cells at 72h. No synergistic effect was observed in L-540 cells.
(e) Representative western blot assay of HL cells after treatment with 25-mm UO126 or PD98059 with or without 1-mm AZD1480 for 72h.
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increasing concentrations of AZD1480 (0.1–5mM) completely
inhibited JAK3 Y980 phosphorylation. In contrast, when HD-LM2
and L-428 cells were incubated with AZD1480, a paradoxical
increase in JAK2 Y1007/1008 and TYK2 Y1054/1055 phospho-
rylation was observed after 72h of incubation (Figure 3a).
The hyperphosphorylation of JAK2 at the activation loop was
conﬁrmed using two antibodies obtained from different clones.
The phosphorylation of the immediate downstream target
STAT3 was abrogated at the same time point in all the three
cell lines (Figure 1b), suggesting that the function of the JAKs
was effectively inhibited by AZD1480.
When JAKs phosphorylation was analyzed over a shorter time
period, a strong increase in JAK2 Y1007/1008 phosphorylation
was observed in HD-LM2 and L-428 cells after 30min of
incubation with 1mM AZD1480 (Supplementary Figure S1A),
whereas JAK3 Y980 phosphorylation was abrogated in L-540
cells (Supplementary Figure S1A). The phosphorylation of the
immediate downstream target STAT3 was abrogated at the same
time point (30min) in all the three cell lines, suggesting that the
function of the JAKs was effectively inhibited after 30min of
incubation with AZD1480 (Supplementary Figure S1A).
AZD1480 induces a negative-feedback loop involving
phosphorylation ERK1/2 and p38
As AZD1480 inhibition of STATs activity did not translate into
antiproliferative activity in two cell lines, we hypothesized that
these cells may depend on other signaling pathways to promote
their survival. To test this hypothesis, we examined the effect of
AZD1480 on ERK, p38 and phosphatidylinositol-3 kinase/AKT
signaling pathways, which are known to promote HL survival.
We found that AZD1480 had no effect on phosphatidylinositol-
3 kinase/AKT signaling in any of these cell lines (data not
shown). In contrast, AZD1480 increased the levels of ERK and
p38 phosphorylation in the resistant HD-LM2 and L-428 cells,
whereas it inhibited ERK and p38 phosphorylation in the
sensitive L-540 cells (Figure 3b). To deﬁne the mechanism of
ERK and p38 activation in the two resistant cell lines, we ﬁrst
assessed the expression and activation levels of the Src
homology 2 domain-containing protein phosphatase 2 (SHP-2)
and SOCS-3 (a STAT3 target gene
21), two known regulators of
JAK/STAT and mitogen-activated protein kinase (MAPK) signal-
ing. In fact, SHP-2 has been reported to be a negative regulator
of the JAK/STAT activation, whereas having a positive effect on
ERK activation.
22–25 Furthermore, numerous studies have
described enhanced SHP-2 and ERK activation after SOCS-3
deletion in both in vitro and in vivo models, postulating a
negative-feedback loop between SOCS-3 and SHP-2.
22,23,26
Consistent with the described changes in ERK phosphorylation
status, after 72h of incubation with increasing doses of
AZD1480 (0.1–5mM), an increase in SHP-2 phosphorylation
on Tyr542 (the major site of SHP-2 activation) coupled with
SOCS3 downregulation was observed in the HD-LM2 and L-428
cell lines, but not in the L-540 cells (Figure 3b). On the other
hand, in the L-540 cells, SOCS3 downregulation was not
coupled with SHP-2 hyperphosphorylation, and ERK phospho-
rylation was in fact inhibited after treatment with AZD1480,
suggesting a different model of MAPK activation in this cell line.
The activation of p38 signaling observed in the HD-LM2 and
L-428 cell lines after incubation with AZD1480 was probably
related to the activity of autocrine and paracrine chemokine and
cytokine loops, triggered by SHP-2/ERK activation. Over a
shorter time period, we observed a strong correlation between
SOCS-3 downregulation and SHP-2/ERK activation in the
HD-LM2 cell line after 6h of incubation with AZD1480,
whereas in the L-540 cell line, ERK phosphorylation was
inhibited without an increase in SHP-2 phosphorylation or a
decrease in SOCS-3 levels (Supplementary Figure S1D).
AZD1480 determines increased production of the
chemokines IP-10, IL-8 and RANTES in HL cells
The interaction between HRS cells and the surrounding reactive
inﬁltrate provides an environment that supports the growth and
survival of HRS cells through a complex network of autocrine
and paracrine loops involving a variety of cytokines and
chemokines.
1,27 The chemokines IP-10, RANTES and IL-8 are
known to be upregulated by MAPK (ERK and p38) activation and
have previously been reported to have a role in tumorigenesis
and Hodgkin lymphomagenesis by promoting cell proliferation
and survival.
1,27–31 Consistent with the observed changes in
SHP2, ERK and p38 phosphorylation, AZD1480 increased the
production of IP-10, RANTES and IL-8 in the supernatants of the
resistant HD-LM2 and L-428, and not the sensitive L-540 cells.
(Figure 3c). This data suggest that the efﬁcacy of AZD1480 may
have been attenuated in the HD-LM2 and L-428 cells by an
autocrine negative-feedback loop involving cytokines that
activate ERK/p38 survival signaling pathway.
MEK inhibitors enhance the efﬁcacy of AZD1480 in the
HD-LM2 and L-428 cell lines
To assess whether the observed activation of the SHP-2/ERK
pathway is involved in the resistance to JAK/STAT inhibition, HL
cells were treated with 1mM AZD1480 in combination with two
commercially available MEK inhibitors (UO126 and PD98059).
Cells were incubated with increasing concentrations of UO126
or PD98059 (10–100mM), with or without 1mM AZD1480 for
24, 48 and 72h, and cell viability was assessed using the MTS
assay. Both UO126 and PD98059 enhanced the effect of
AZD1480 in the HD-LM2 and L-428 cells at 72h (Figure 3d).
This effect was associated with inhibition of AZD1480-induced
ERK phosphorylation (Figure 3e).
Immunoregulatory effects of AZD1480 in HL cells
PD-L1 and PD-L2 are members of the B7 family, which inhibit
T-cell function by interacting with the programmed cell death 1
receptor expressed on T cells. PD-L1 and PD-L2 have been
reported to be regulated by the JAK/STAT pathway or the MAPK
pathway, depending on the cellular context.
9,11,13
Therefore, we assessed the effect of AZD1480 on PD-L1 and
PD-L2 expression in HL cells by ﬂow cytometry. After
incubation with AZD1480 1mM for 72h, we observed a
signiﬁcant downregulation of PD-L1 and PD-L2 in the PD-L1/
PD-L2-positive HL cell lines HD-LM2 and L-540 (Figure 4a
and b). No signiﬁcant dowregulation was detected following
incubation with MEK inhibitors (UO126 and PD98059 25mM
for 72h) in the L-540 cell line (data not shown). On the other
hand, in the HD-LM2 cell line, an increase in the activation of
ERK was observed after incubation with AZD1480, ruling out a
role of this pathway in the regulation of PD ligands expression in
this cell line (Figure 3b).
Given the potent inhibition of STAT proteins phosphorylation
observed with low doses AZD1480 (0.1–1mM), we also assessed
the effect of AZD1480 on the expression of STAT-regulated
cytokines and chemokines involved in HL cell survival (IL-6)
and immune escape (IL-13, TARC), focusing on the three cell
lines with baseline JAK/STAT activation. Following incubation
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analyzed by enzyme-linked immunosorbent assay; consistent
with the inhibition of STAT3 and STAT6 phosphorylation,
decreased levels of IL-6, IL-13 and TARC were observed in
HD-LM2, L-428 and L-540 (Figure 4b).
High concentrations of AZD1480 promote early G2/M
arrest and cell death in HL cells by inhibiting Aurora
kinases
Higher concentrations (5mM) of AZD1480 promoted a marked
increase in the G2/M fraction in all four cell lines after 24h of
incubation, especially pronounced in HD-LM2 and L-428 cells
(Figure 5a and b). In contrast, treatment with a lower AZD1480
concentration (1mM) for 24h did not signiﬁcantly affect the cell
cycle fractions (Figure 5a and b). As AZD1480 was reported to
inhibit Aurora A kinase in enzymatic assays,
14 we assessed
whether the signiﬁcant increase in the G2/M fraction observed
in HL cell lines after incubation with 5mM AZD1480 was related
to the inhibition of Aurora A.
First, we analyzed the baseline expression of Aurora A and B
kinases in exponentially growing HL cells by western blotting.
All four cell lines showed overexpression of Aurora A and B, and
histone H3, compared with PBMCs from healthy donors
Figure 4 Immunoregulatory effects of AZD1480 in HL cells. (a) Representative experiment demonstrating the effect of AZD1480 on PD-L1 and
PD-L2 expression in HD cell lines. Cells were incubated with medium or AZD1480 1mm for 72h, and PD-L1 and PD-L2 expression levels were
examined by ﬂow cytometry. The bar graphs summarize the results from three independent experiments. Each value represents the mean of three
independent experiments. *Denotes P-value less than 0.05, and **denotes P-value less than 0.005. (b) Cells were incubated with medium or
AZD1480 1mm for 72h, and supernatants were examined for cytokine levels by enzyme-linked immunosorbent assay. The bar graphs summarize
the results from three independent experiments. Each value represents the mean of three independent experiments. *Denotes P-value less than
0.05 and **denotes P-value less than 0.005.
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rylation at Thr288 in the activation loop. Thus, to determine
the effect of AZD1480 on Aurora A kinase, we evaluated the
levels of autophosphorylation at Thr288 by western blotting.
Cells were pretreated with nocodazole (400ng/ml) for 18h,
to achieve a mitotic block, and then exposed to AZD1480
(1 or 5mM) with or without the proteasome inhibitor MG132
(20mM; to prevent a potential override of the nocodazole-
induced mitotic block by proteasome-dependent mechanisms)
for 3h (Figure 5d). Dose-dependent inhibition of Aurora A was
detected after 3h of incubation in all the four cell lines, and
Thr288 autophosphorylation was abrogated when a higher dose
of AZD1480 (5mM) was used (Figure 5d). These ﬁndings are
consistent with the analysis of the cell cycle fractions, showing
major dose-dependent changes in the cell cycle after incubation
with AZD1480. In L-428 and L-540 cells, a dose-dependent
inhibition of the phosphorylation of histone H3 at Ser10 was
observed, suggesting a dual inhibition of Aurora A and B in these
cell lines.
Discussion
In this study, we described the pleiotropic activity of AZD1480
in HL-derived cell lines, showing a dual mechanism of action:
(1) a direct dose-dependent cytotoxic effect achieved by two
Figure 5 AZD1480 induces G2/M cell cycle arrest by inhibition of Aurora A in HL cell lines. (a) Cells were incubated with AZD1480 (1 or 5mm)
for 24h, and the cell cycle was analyzed by ﬂow cytometry. AZD1480 induced an increase in the G2/M fraction only when a high concentration
(5mm) was used. (b) Bar graphs summarizing cell cycle analysis results; each value is the mean of three independent experiments. (c) Baseline
expression status of Aurora kinases and histone H3 in HL cell lines. Whole-cell lysates of untreated HL cells were examined by western blotting for
Aurora A, Aurora B, histone H3 and p-histone H3 (Ser10). (d) Representative western blot assay showing the effect of treatment with 1 and 5mm
AZD1480 (with or without MG132 20mm) for 3h on Aurora A, Aurora B and histone H3 phosphorylation (Ser 10) in HL cells. Cells were pretreated
with nocodazole 400ng/ml for 18h to achieve a mitotic block.
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pathway (at low doses) and the Aurora kinases (at higher doses)),
resulting in apoptosis and G2/M cell cycle arrest; (2) an indirect
effect on tumor microenvironment achieved through impair-
ment of mechanisms involved in survival and immune evasion,
with inhibition of Th2 cytokine and chemokine secretion and
downregulation of PD-L1 and PD-L2 expression (Figure 6).
This study provided several observations that will be
important for the development of JAK/STAT pathway-targeted
therapy in HL. We demonstrated that the expression of active
pJAK2 protein did not predict response to the JAK2 inhibitor
AZD1480, and therefore, in the clinical setting, pJAK2 expres-
sion may not be a useful biomarker for selecting patients for
AZD1480 therapy. Moreover, even though submicromolar
concentrations of AZD1480 effectively inhibited the function
of the target JAK2 protein, as evident by dephosphorylation of
the downstream STAT proteins, these concentrations had no
signiﬁcant antiproliferative effect in the HD-LM2 and L-428 cell
lines. Submicromolar concentrations of AZD1480 inhibited the
phosphorylation of STAT1, STAT3, STAT5 and STAT6, with no
apparent differential effect. This is in contrast with what was
recently reported with selective silencing of STAT6 gene
expression experiments, as it resulted in activation of STAT1 in
the same cell line, which may have contributed to induction of
cell death.
32 At low concentrations (0.1–1mM), AZD1480
displayed predominantly immunomodulatory effects, down-
regulating the expression of Th2 cytokines and chemokines
(IL-13 and TARC), and factors involved in mechanisms of
immune escape (PD-L1 and PD-L2). Collectively, these data
suggest that AZD1480 may enhance anti-tumor immunity by
increasing the activity of cytotoxic T cells (through down-
regulation of PD-L1 and PD-L2, and inhibition of an unfavorable
Th2 cytokine proﬁle).
Regarding the mechanism involved in the resistance of the
HD-LM2 and L-428 cell lines to low doses of AZD1480, this
may be related to a negative-feedback loop involving hyperphos-
phorylation of JAK2 and activation of secondary ERK and p38
signaling pathways that promote HL survival. In fact, even
though the function of JAK2 was effectively inhibited as
demonstrated by the abrogation of downstream STATs phos-
phorylation, we observed a paradoxical increase in the JAK2
and TYK2 phosphorylation status after incubation with
AZD1480. Although the mechanism of AZD1480-induced
JAK2 phosphorylation is currently unclear, it may be related to
the conformational changes and/or induction of negative-feed-
back loops involving activating cytokines. Similar results were
previously reported by Okuzumi et al.
33, who described
paradoxical hyperphosphorylation of AKT after treatment with
an ATP-competitive kinase inhibitor. On the other hand, our
data suggest that AZD1480-induced ERK and p38 phosphoryla-
tion may involve two major regulators of the JAK and MAPK
pathways: SOCS-3 (a known STATs target gene)
21 and SHP-2
(a protein phosphatase known to activate ERK signaling).
24
According to other reports showing sustained SHP-2 and ERK
activation after SOCS-3 deletion in various in vitro and in vivo
models,
22,23,25 we observed a similar regulation of MAPK
signaling, at least in the HD-LM2 and L-428 cells that were
resistant to AZD1480. These observations are consistent with a
model in which SOCS-3, JAK2 and SHP-2 are reciprocally
regulated as previously reported.
22 It is important to note that
these molecular negative-feedback loop events were associated
with an increase in the level of IL-8, IP-10 and RANTES
cytokines in HL cell lines supernatants. As RANTES may activate
and phosphorylate JAK2 and TYK2, it is possible that the
increased baseline levels of pJAK2 and pTYK2 in the HDLM2
and L428 cells, but not L-540 cells, may be related to the
differential production of RANTES and other cytokines among
these cell lines. Similarly, an increased secretion of these
cytokines, such as RANTES, in response to AZD1480 treatment,
may have also contributed to the observed JAK2 hyperpho-
sphorylation, following incubation with AZD1480.
34 This
observation should be further investigated in the clinical setting
to determine whether changes in the levels of certain cytokines
in serial plasma specimens may serve as a surrogate biomarker
for resistance to AZD1480 therapy in HL patients. The fact that
AZD1480 synergized with two different MEK inhibitors (UO126
and PD98059) in the resistant cell lines characterized by
AZD1480-induced ERK hyperactivation strongly supports the
hypothesis that ERK hyperactivation may be an important
mechanism of resistance to the JAK inhibition in HL.
In this study, we show that higher concentrations of AZD1480
inhibited Aurora kinases and induced G2/M cell cycle arrest and
cell death in all HL cell lines, irrespective of JAK/STAT pathway
status. Aurora A has a crucial role in mitotic bipolar spindle
formation and localizes to centrosomes at the proximal mitotic
spindle, whereas Aurora B localizes to kinetochores, phospho-
rylates histone H3 at Ser10, and has a role in chromosome
alignment and cytokinesis.
35 Inhibition of Aurora kinases
promotes G2/M arrest and apoptosis in multiple human cancers
including lymphoid malignancies (multiple myeloma and adult
T-cell leukemia),
36–38 but no data are available, which suggest a
role of Aurora kinases in Hodgkin lymphomagenesis. We found
that Aurora A and B kinases were overexpressed in the four HL
cell lines compared with PBMCs from healthy donors. AZD1480
promoted a dose-dependent inhibition of Aurora A autophos-
phorylation at Thr288 in all the four HL cell lines. We observed
a tight correlation between the dose-dependent inhibition of
Aurora A and the changes observed in cell cycle fraction and
apoptosis in HL cells. A dose-dependent inhibition of histone
H3 phosphorylation at ser 10 was detected in two cell lines
(L-428 and L-540), suggesting that high doses of AZD1480 may
also inhibit Aurora B in these cell lines. Due to the fact that
Reed–Sternberg cells account for less than 5% of the entire
tumor mass, being very rare in the affected lymph nodes, we
were not able to microdissect viable primary HRS cells from
patients’ lymph nodes to perform in vitro viability and functional
assays.
Figure 6 Model for AZD1480 activity in HL cells. A model showing
the dual, dose-dependent mechanism of action of AZD1480 in HL
cells. At low doses (0.1–1mm), AZD1480 inhibits the JAK/STAT
pathway, showing predominantly immunoregulatory effects (down-
regulation of IL-6, IL-13, TARC, PD-L1 and PD-L2). At high doses
(5mm), AZD1480 also inhibits the Aurora kinases, promoting G2/M
arrest and apoptosis in HL cells.
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JAK/STAT activation in cultured HL cells at submicromolar
concentrations, by blocking the function of JAKs (including
JAK3) and determining immunomodulatory effects. Moreover,
the two cell lines (HD-LM2 and L-428), which showed MAP
kinase hyperactivation following treatment with AZD1480, were
resistant to the drug at concentrations clearly able to inhibit
STATs phosphorylation. The fact that different MEK inhibitors
synergized with AZD1480 in these two resistant cell lines,
suggest that this negative-feedback loop activating MAP kinases
could be an important mechanism of resistance to AZD1480.
In summary, our results provide preclinical rationale for
further clinical investigation of AZD1480 in HL and provide
molecular rationale for incorporating biomarker studies accord-
ing to the primary target inhibition (JAK/STAT vs Aurora kinases).
Furthermore, our data demonstrate the importance of evaluating
the in vivo effect of small molecule inhibitors on secondary
signaling pathways that may mediate resistance to therapy and
provide informations on combination strategies.
In fact, these data could be tested in the clinical setting by
performing sequential biopsies from patients treated with
AZD1480, to determine its in vivo effect on JAK2, ERK, p38
and Aurora A, and to correlate the phosphorylation status of
these proteins with the response to AZD1480 therapy. Finally,
these data provide a mechanistic rationale for combination
strategies aiming at blocking the AZD1480-induced activation
of ERK and p38.
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